A clinical and radiological evaluation of DFDBA with amniotic membrane versus bovine derived xenograft with amniotic membrane in human periodontal grade II furcation defects
- 361 Downloads
The purpose of the present study was to clinically and radiographically evaluate and compare the efficacy of demineralized freeze dried bone allograft (DFDBA) and bovine derived xenogenic bone graft (BDX) [Bio-Oss] with amniotic membrane (AM) as guided tissue regeneration (GTR) in the treatment of human periodontal Grade II buccal furcation defects. Ten patients suffering from chronic periodontitis, displaying bilateral Grade II buccal furcation defect, were randomly treated using DFDBA with AM (Experimental site A) or using bovine derived xenograft (BDX) with AM (Experimental site B). The clinical and radiographic parameters were recorded at baseline, 6 and 9 months. Healing was uneventful in all patients except one site which was treated with BDX + AM. At 9 months after therapy, soft tissue measurements for the DFDBA + AM group showed pocket depth (PD) reduction of 4.7 mm ± 0.58, and relative attachment level gain of 4.8 mm + 0.32, while the BDX + AM group showed a PD reduction of 4.4 mm ± 0.27, and AL gain of 5.1 mm ± 0.09. Osseous measurements showed bone fill of 2.1 mm ± 0.36 for the DFDBA + AM group and 2.43 mm ± 0.38 for the BDX + AM group. Percentage gain in bone was 76.3% for the DFDBA + AM group and 79.6% for the BDX + AM group. Statistical analysis revealed there was no statistical difference between the two materials in all measurements. Within the limits of the present study, it can be concluded that: (1) at 9 months after surgery both therapies resulted in significant PD reductions and CAL gains and (2) significant improvement was seen in bone fill and percentage gain with both the material, however, there was no significant difference between both.
KeywordsRegenerative periodontal therapy Controlled clinical study Bovine derived xenograft DFDBA Amniotic membrane
We would like to thank; (1) Tissue Bank, Tata Memorial Hospital, Mumbai, India for providing us the DFDBA and AM. (2) Department of Oral Medicine and Radiology, KLE’s Institute of Dental Sciences, Belgaum, Karnataka, India for allowing us to use RVG.
- Camargo PM, Lekovic V, Weinlaender M, Nedic M, Vasilic N, Wolinsky LE, Kenney EB (2000) A controlled re-entry study on the effectiveness of bovine porous bone mineral used in combination with a collagen membrane of porcine origin in the treatment of intrabony defects in humans. J Clin Periodontol 27:889–896PubMedCrossRefGoogle Scholar
- Carranza FA, Newman MG (1996) Clinical Periodontology, 8th edn. WB Saunders & Co, Philadelphia, pp 61–82Google Scholar
- Cohen P, Tobaly K, Danan M, Pare C, Sauven J, Brion M (1990) Treatment of intraosseous lesions with anorganic bovine bone plus collagen. Entret Bichat, Odontol et Stomatol xx:91–94Google Scholar
- Cortellini P, Bowers GM (1995) Periodontal regeneration of Intrabony defects: An evidence-based treatment approach. Int J Periodontics Restorative Dent 15(12):8–145Google Scholar
- Dragoo M, Sullivan M (1973) A clinical and histologic evaluation of autogenous iliac bone grafts in humans. Part I. wound healing 2–8 months. J of Periodontol 44:599–612Google Scholar
- Libin BM, Ward HL, Fishman L (1975) Decalcified, lyophilized bone allografts for use in human periodontal defects. J Periodontol 46(5):1–56Google Scholar
- Mellonig J (1984) Decalcified freeze-dried bone allograft as an implant material in human periodontal defects. Int J Periodontol Restorative Dent 4:40–55Google Scholar
- Mellonig JT (1992) Autogenous and allogeneic bone grafts in periodontal therapy. Crit Rev Oral Biol 3:333–352Google Scholar
- Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian Alexander (2008) Properties of the amniotic membrane for potential use in tissue engineering. Eur Cells Mater 15:88–99Google Scholar
- Sculean A, Chiantella GC, Windisch P, Gera I, Reich E (2002) Clinical evaluation of an enamel matrix protein derivative (Emdogains) combined with a bovine derived xenograft (Bio-Oss) for the treatment of intrabony periodontal defects in humans. Int J Periodontics Restorative Dent 22:259–267PubMedGoogle Scholar